These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10147132)

  • 1. Clinical decision making vs programme evaluation perspectives.
    Levine MN; Gafni A
    Pharmacoeconomics; 1993 Sep; 4(3):228-31. PubMed ID: 10147132
    [No Abstract]   [Full Text] [Related]  

  • 2. Breast cancer: clinical decision making.
    Hayes JD; Clark EJ
    Pharmacoeconomics; 1993 Sep; 4(3):226-8. PubMed ID: 10147131
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results.
    Hillner BE; Smith TJ; Desch CE
    JAMA; 1992 Apr; 267(15):2055-61. PubMed ID: 1552641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of bone marrow transplantation in the management of advanced local disease.
    Safah H; Weiner RS
    Surg Oncol Clin N Am; 1995 Oct; 4(4):735-49. PubMed ID: 8535908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy in breast cancer: efficacy and cost utility.
    Corry JF; Lønning PE
    Pharmacoeconomics; 1994 Mar; 5(3):198-212. PubMed ID: 10146895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral blood stem cell transplant in breast cancer.
    Crilley P; Goldstein LJ
    Semin Oncol; 1995 Jun; 22(3):238-49. PubMed ID: 7777868
    [No Abstract]   [Full Text] [Related]  

  • 8. Last chance therapies and managed care. Pluralism, fair procedures, and legitimacy.
    Daniels N; Sabin JE
    Hastings Cent Rep; 1998; 28(2):27-41. PubMed ID: 9589291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How one company decides when to pay for experimental therapies.
    Oncology (Williston Park); 1995 Jul; 9(7):666. PubMed ID: 8924376
    [No Abstract]   [Full Text] [Related]  

  • 10. New approach to administrative medical decision-making: evidence-based medicine using high dose chemotherapy/bone marrow transplant for breast cancer.
    Lucey C; Westphal JR
    South Med J; 1998 Feb; 91(2):196-201. PubMed ID: 9496875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer.
    Peters WP; Rogers MC
    N Engl J Med; 1994 Feb; 330(7):473-7. PubMed ID: 8289855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out.
    Smith GA; Henderson IC
    Important Adv Oncol; 1995; ():201-14. PubMed ID: 7672807
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant chemotherapy for breast cancer: discordance between physicians' perception of benefit and the results of clinical trials.
    Rajagopal S; Goodman PJ; Tannock IF
    J Clin Oncol; 1994 Jun; 12(6):1296-304. PubMed ID: 8201392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effective use of autologous bone marrow transplantation: few answers, many questions, and suggestions for future assessments.
    Hillner BE; Smith TJ; Desch CE
    Pharmacoeconomics; 1994 Aug; 6(2):114-26. PubMed ID: 10147437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness and other assessments of adjuvant therapies for early breast cancer.
    Hillner BE; Smith TJ
    Oncology (Williston Park); 1995 Nov; 9(11 Suppl):129-34. PubMed ID: 8608043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
    Naeim A; Keeler EB
    Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients.
    Marino P; Siani C; Bertucci F; Roche H; Martin AL; Viens P; Seror V
    Breast Cancer Res Treat; 2011 Sep; 129(2):401-9. PubMed ID: 21061059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment: adjuvant therapy decisions in node-negative breast cancer.
    Anand A; Anand N; Anand A
    Ann Pharmacother; 1995 Sep; 29(9):940-1. PubMed ID: 8547753
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer.
    Bonastre J; Marguet S; Lueza B; Michiels S; Delaloge S; Saghatchian M
    J Clin Oncol; 2014 Nov; 32(31):3513-9. PubMed ID: 25287824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Federal courts still split on autologous bone marrow transplants.
    Margolis RE
    Healthspan; 1992 Dec; 9(11):20-2. PubMed ID: 10123554
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.